Results 231 to 240 of about 175,800 (301)

Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Following promising results in a phase II trial evaluating GAMMA as salvage therapy for relapsed germ cell tumours (GCT) who had progressed on cisplatin‐based chemotherapy, the GAMMA regimen was adopted into clinical practice at St Bartholomew's Hospital.
Nasreen Abdul Aziz, Kenrick Ng, Prabhakar Rajan, Jonathan Shamash   +3 more
wiley   +1 more source

Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy. [PDF]

Clin Mol Hepatol
Hassanel DNBP, Sharma A.
europepmc   +1 more source

Giant Mediastinal Teratoma in a Child: A Case Report With a Brief Review of the Literature

Clinical Case Reports, Volume 14, Issue 5, May 2026.
Contrast‐enhanced axial chest CT showing a large, well‐circumscribed mediastinal mass measuring approximately 15.9 × 14.1 cm (maximum axial dimensions). The lesion is predominantly of fluid attenuation, occupies nearly the entire left hemithorax, and produces marked rightward deviation of the mediastinum, compression of the contralateral lung ...
Urías Hernandez Lopez, Pastor Thomas Olivares, Alex Fernández Arrieta, Juan Correa Palacio, Aura Guevara Díaz, Ana Guerra Urquijo   +5 more
wiley   +1 more source

Extracellular vesicle-derived lncRNA-NEAT1 serves as potential biomarker for the early diagnosis of hepatocellular carcinoma. [PDF]

Transl Cancer Res
Li C, Wu Q, Hong H, Zhou L.
europepmc   +1 more source

Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is an advanced disease with poor prognosis and limited treatment options. Conversion therapy integrating locoregional and systemic modalities may expand surgical eligibility, but achieving pathological complete response (pCR) remains rare.
Weidong Zhang, Huihui Shen, Xinglong Wang, Jingjing Gu, Minghai Shen, Qinghua Zhang   +5 more
wiley   +1 more source

Case Report: Hepatoblastoma with spindle cell sarcomatous metastasis in a 14-year-old girl. [PDF]

Front Pediatr
Zhang Y, Yu X, Ge J, Wang J, Bai C, Kang S, Wang J.   +6 more
europepmc   +1 more source

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai   +10 more
wiley   +1 more source

Long-term survival after multimodal therapy for advanced hepatocellular carcinoma: a case report. [PDF]

Front Immunol
Wu D, Hu G, Wang D, Chen C, Ming B, Luo Z, Wang T, Li H.   +7 more
europepmc   +1 more source

A multi‐centre, prospective trial of a methylation‐based liquid biopsy for early detection of liver cancer in high‐risk populations

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Three hypermethylated cfDNA markers specific to liver cancer, RNF135, CHFR and PAX5, were identified in peripheral blood and used to construct a diagnostic model. The model achieved 94.43% sensitivity and 95.16% specificity in a large clinical validation cohort, with a sensitivity of 93.1% for stage‐I liver cancer. Abstract Background and aims Existing
Ruohan Zhang, Xinrong Yang, Guangming Li, Yinan Deng, Jibing Liu, Hongjun Gao, Jie Zhao, Jianwen Cheng, Xiaofei Zhao, Yang Yang, Zhen Wu, Shuangzhen Gu, Yang Wu, Zhongying Ma, Yanli Liu, Yan Kang, Guangpeng Zhou, Hua Li, Yonghong Zhang, Xiaoliang Han, Jia Fan, Jian Zhou, Kefeng Dou, Kaishan Tao   +23 more
wiley   +1 more source